Could Kymriah Have Become the CAR-T Market Leader in Q4 2020? PORTIA Deprioritized; No Updates on Cilta-cel’s Regulatory Submissions; Novartis and JNJ Q4 2020 Earnings Call Summaries
Here is a brief preview of this blast: On Tuesday, January 26, Novartis (press release / presentation) and JNJ (press release / presentation) held their Q4 2020 earnings calls. Novartis highlighted Kymriah’s FY 2020 WW growth of 68% YoY, while JNJ confirmed the rolling submission of cilta-cel’s BLA in December 2020. Below, Celltelligence provides insights on how Kymriah could become the CAR-T market leader, Novartis’s reprioritization of the Ph1b PORTIA trial (Kymriah + pembrolizumab), and the possibility of an August US approval for cilta-cel.